First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
about
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma.Follicular lymphoma: 2018 update on diagnosis and management.Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.Copanlisib: First Global Approval.Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisibSpotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to dateSuppression of insulin feedback enhances the efficacy of PI3K inhibitors
P2860
Q37578324-010AA372-2B6F-447E-884C-01A6DD2AD581Q38373698-27B9CC9E-8B11-444C-8898-FB1DA8556E72Q38685006-7516DCFE-7DC1-4E33-9329-2C2D7EFE6D66Q39375290-2EC809FA-53FA-427E-817A-8E9425F8C9E6Q41537666-AB7499BD-011E-4F20-957A-FA16E8378A8BQ41994564-FEA633E7-87E3-424F-8AA5-630636C1A2FBQ46333555-08FB2C5F-A741-4B15-9047-7BAB13CD35B1Q47219215-8A5B3C22-CDAC-4537-B40A-16747F327C61Q47584016-0CF5B428-6228-43F0-9E98-590890BA21F9Q47932240-78F0EC28-3DED-4F8B-ACD4-53AFEBD2E0D8Q48138303-49C515E1-531B-4D47-BB99-B61E0D83FFF8Q49887919-5CEAB044-8769-4D6F-8E0E-CC45476F6EA0Q49952154-DA1CE240-EA22-4064-BC57-5FDCF766DFCBQ50055654-A506CC37-5477-4372-B063-DDF50BA67438Q50061541-C72107BC-914B-4338-B8A3-DA4B7EAC4EB4Q55010628-A6CD2EEC-E11B-41B0-8FE1-BF1BA2094318Q58729853-42717CA5-5B9D-4E0F-9D77-F0986BFF9A1FQ58785964-7FC329C3-5CE0-441F-8276-58338644B2D8Q59066873-04F3D998-DE6E-469C-91D7-E5987698EFBF
P2860
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
First-in-human phase I study o ...... s and non-Hodgkin's lymphomas.
@en
First-in-human phase I study o ...... s and non-Hodgkin's lymphomas.
@nl
type
label
First-in-human phase I study o ...... s and non-Hodgkin's lymphomas.
@en
First-in-human phase I study o ...... s and non-Hodgkin's lymphomas.
@nl
prefLabel
First-in-human phase I study o ...... s and non-Hodgkin's lymphomas.
@en
First-in-human phase I study o ...... s and non-Hodgkin's lymphomas.
@nl
P2093
P2860
P356
P1433
P1476
First-in-human phase I study o ...... s and non-Hodgkin's lymphomas.
@en
P2093
A W Tolcher
F G S Toledo
I Genvresse
J C Sachdev
P2860
P304
P356
10.1093/ANNONC/MDW282
P577
2016-10-01T00:00:00Z